View Older Stories
-
Keenova Unveils Clinical Data from Phase 2 Plantar Fibromatosis Study at the ACFAS Annual Meeting
-
Keenova Announces New Manuscript on Plantar Fibromatosis Treatment Patterns in Peer-Reviewed Journal of Foot and Ankle Surgery
-
Keenova Marks 100K Peyronie's Disease Patients--a Major Milestone for an Often-Stigmatized Men's Health Condition
-
Keenova presents Dupuytren's contracture survey at hand surgery meeting
-
Keenova Announces New Dupuytren's Contracture Survey Presentation About Patient Perceptions and Treatment Outcomes
-
Mallinckrodt Reports Third Quarter 2025 Financial Results
-
Mallinckrodt completes Par Health spin-off, rebrands as Keenova Therapeutics
-
Mallinckrodt Completes Spin-Off of Par Health, Introduces Keenova Therapeutics
-
Mallinckrodt to Present Data on Terlipressin at the 2025 American Association for the Study of Liver Diseases (AASLD) Annual Meeting
-
Mallinckrodt publishes Acthar Gel arthritis treatment study results
-
Mallinckrodt Announces Publication of Findings on Treatment Patterns and Outcomes in Patients with Two Types of Arthritis Treated with Acthar® Gel (repository corticotropin injection)
-
Mallinckrodt plc Reports Financial Results for Second Quarter 2025 and Provides Guidance
-
Mallinckrodt completes merger with Endo to form combined therapeutics company
-
Mallinckrodt, Endo Complete Merger to Create Global, Scaled, Diversified Therapeutics Leader
-
Mallinckrodt Announces Publication of Real-World Insights on Patient Experience with Acthar® Gel (repository corticotropin injection) Single-Dose Pre-filled SelfJect™ Injector
-
Mallinckrodt (MNK) and Endo (NDOI) Announce Planned Leadership Team for Merged Company
-
Mallinckrodt, Endo Announce Planned Leadership Team for Merged Company
-
Mallinckrodt Presents Data on Real-World Outcomes with Acthar® Gel (repository corticotropin injection) at the International Congress on Systemic Lupus Erythematosus (LUPUS 2025)
-
Mallinckrodt and Endo Announce Significant Progress in Proposed Merger
-
Mallinckrodt plc Reports First Quarter 2025 Financial Results and Reaffirms Full-Year Guidance
-
Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection at the 2025 Digestive Disease Week (DDW) Annual Meeting
-
Mallinckrodt (MNK) and Endo (NDOI) to Combine
-
Mallinckrodt plc Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides 2025 Guidance
-
Mallinckrodt and Endo to Combine to Create a Global, Scaled, Diversified Pharmaceuticals Leader
-
Mallinckrodt Completes Divestiture of Therakos® Business
-
Mallinckrodt (MNK) Presents Data on TERLIVAZ® (terlipressin) for Injection in Patients with Hepatorenal Syndrome (HRS) at the 2024 American Association for the Study of Liver Diseases
-
Mallinckrodt Presents Data on TERLIVAZ® (terlipressin) for Injection in Patients with Hepatorenal Syndrome (HRS) at the 2024 American Association for the Study of Liver Diseases (AASLD) Annual Meetin
-
Mallinckrodt plc Reports Third Quarter 2024 Financial Results and Raises Full Year Guidance
-
Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection at the 2024 American Association for the Study of Liver Diseases (AASLD) Annual Meeting
-
Mallinckrodt Presents Data on TERLIVAZ® (terlipressin) for Injection in Patients with Hepatorenal Syndrome-Acute Kidney Injury (HRS-AKI) at the American College of Gastroenterology (ACG) Annual Meeti
-
Mallinckrodt Presents Data on TERLIVAZ® (terlipressin) for Injection in Patients with Hepatorenal Syndrome (HRS) at Kidney Week 2024
-
Mallinckrodt Announces an Expanded Rollout of the INOmax® EVOLVE™ DS Delivery System in U.S. Hospitals
-
Mallinckrodt Announces Publication of Human Factors Studies and Arthritis Foundation Ease of Use® Certification of Acthar® Gel (repository corticotropin injection) Single-Dose Pre-filled SelfJect™
-
Mallinckrodt plc Reports Second Quarter 2024 Financial Results and Raises Full Year Guidance
-
Mallinckrodt Announces Availability of Acthar® Gel (repository corticotropin injection) Single-Dose Pre-filled SelfJect™ Injector in the U.S.
-
Mallinckrodt (MNK) to Sell Therakos Business to CVC for $925M
-
Mallinckrodt Reaches Agreement to Sell Therakos® Business to CVC for $925 Million
-
Mallinckrodt Presents Data on TERLIVAZ® (terlipressin) for Injection in Patients with Hepatorenal Syndrome (HRS) at the 2024 European Association for the Study of the Liver (EASL) Congress
-
Mallinckrodt Presents Data on TERLIVAZ® (terlipressin) for Injection in Patients with Hepatorenal Syndrome (HRS) at the 2024 Digestive Disease Week® (DDW)
-
Mallinckrodt plc Reports First Quarter 2024 Financial Results and Reaffirms Full Year Guidance
-
Mallinckrodt plc Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides 2024 Guidance
-
Mallinckrodt Announces Journal Publication of Real-World Data on Acthar® Gel (repository corticotropin injection) to Treat Symptomatic Sarcoidosis in African American and Non-African American Patient
-
Mallinckrodt Announces U.S. FDA Approval of Supplemental New Drug Application for Acthar® Gel (repository corticotropin injection) Single-Dose Pre-filled SelfJect™ Injector
-
Mallinckrodt (MNK) Presents New Data on TERLIVAZ
-
Mallinckrodt Presents New Data on TERLIVAZ® (terlipressin) for Injection at the Society of Critical Care Medicine (SCCM) 2024 Critical Care Congress
-
Mallinckrodt (MNK) Reports its Plan and the Scheme of Arrangement Became Effective, Debtors Emerged from the Chapter 11 Cases
-
Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the American Society of Nephrology (ASN) Kidney Week 2023 Scientific Meetin
-
Mallinckrodt (MNKTQ) Presents Latest Health Economics Data on Acthar Gel
-
Mallinckrodt Presents Latest Health Economics Data on Acthar® Gel (Repository Corticotropin Injection) at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023
-
Buxton Helmsley Issues Statement on Mallinckrodt plc. Bankruptcy Filing and Disclosures Revealing Apparently Concealed Intangible Asset Depreciation Expenses

